INGENOL MEBUTATE: 3,025 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
3,025
Total FAERS Reports
5 (0.2%)
Deaths Reported
58
Hospitalizations
3,025
As Primary/Secondary Suspect
19
Life-Threatening
36
Disabilities
Jan 23, 2012
FDA Approved
Discontinued
Status
Yes
Generic Available
FDA Application: 202833 ·
Patent Expires: May 15, 2033 · First Report: 2012 · Latest Report: 20211103
What Are the Most Common INGENOL MEBUTATE Side Effects?
#1 Most Reported
Application site erythema
1,373 reports (45.4%)
#2 Most Reported
Application site pain
1,012 reports (33.5%)
#3 Most Reported
Application site vesicles
843 reports (27.9%)
All INGENOL MEBUTATE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Application site erythema | 1,373 | 45.4% | 0 | 12 |
| Application site pain | 1,012 | 33.5% | 0 | 13 |
| Application site vesicles | 843 | 27.9% | 0 | 4 |
| Application site exfoliation | 586 | 19.4% | 0 | 4 |
| Drug administered at inappropriate site | 500 | 16.5% | 0 | 7 |
| Application site swelling | 489 | 16.2% | 0 | 7 |
| Application site scab | 451 | 14.9% | 0 | 5 |
| Application site dryness | 365 | 12.1% | 0 | 0 |
| Incorrect drug administration duration | 339 | 11.2% | 0 | 9 |
| Application site pruritus | 291 | 9.6% | 0 | 2 |
| Inappropriate schedule of drug administration | 250 | 8.3% | 0 | 3 |
| Drug administration error | 214 | 7.1% | 0 | 3 |
| Incorrect dose administered | 214 | 7.1% | 0 | 1 |
| Eye swelling | 198 | 6.6% | 1 | 7 |
| Application site discharge | 188 | 6.2% | 0 | 0 |
| Application site reaction | 160 | 5.3% | 0 | 5 |
| Application site erosion | 123 | 4.1% | 0 | 1 |
| Drug ineffective | 119 | 3.9% | 0 | 0 |
| Application site discolouration | 115 | 3.8% | 0 | 0 |
| Headache | 108 | 3.6% | 1 | 4 |
Who Reports INGENOL MEBUTATE Side Effects? Age & Gender Data
Gender: 65.1% female, 34.9% male. Average age: 61.4 years. Most reports from: US. View detailed demographics →
Is INGENOL MEBUTATE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2012 | 5 | 0 | 0 |
| 2013 | 49 | 0 | 5 |
| 2014 | 319 | 0 | 7 |
| 2015 | 488 | 2 | 12 |
| 2016 | 422 | 0 | 8 |
| 2017 | 191 | 0 | 7 |
| 2018 | 163 | 1 | 3 |
| 2019 | 151 | 0 | 3 |
| 2020 | 33 | 0 | 1 |
| 2021 | 3 | 0 | 0 |
What Is INGENOL MEBUTATE Used For?
| Indication | Reports |
|---|---|
| Actinic keratosis | 1,751 |
| Product used for unknown indication | 582 |
| Precancerous skin lesion | 416 |
| Solar lentigo | 77 |
| Actinic cheilitis | 43 |
| Skin cancer | 38 |
| Squamous cell carcinoma | 19 |
| Basal cell carcinoma | 18 |
| Hyperkeratosis | 16 |
| Precancerous cells present | 12 |
INGENOL MEBUTATE vs Alternatives: Which Is Safer?
INGENOL MEBUTATE vs INLYTA
INGENOL MEBUTATE vs INOTERSEN
INGENOL MEBUTATE vs INOTUZUMAB OZOGAMICIN
INGENOL MEBUTATE vs INSULIN
INGENOL MEBUTATE vs INSULIN ASPART
INGENOL MEBUTATE vs INSULIN ASPART\INSULIN DEGLUDEC
INGENOL MEBUTATE vs INSULIN BEEF
INGENOL MEBUTATE vs INSULIN DEGLUDEC
INGENOL MEBUTATE vs INSULIN DEGLUDEC\LIRAGLUTIDE
INGENOL MEBUTATE vs INSULIN DETEMIR
Official FDA Label for INGENOL MEBUTATE
Official prescribing information from the FDA-approved drug label.